HK1198541A1 - Method for improving the stability of purified factor viii after reconstitution - Google Patents

Method for improving the stability of purified factor viii after reconstitution Download PDF

Info

Publication number
HK1198541A1
HK1198541A1 HK14112047.2A HK14112047A HK1198541A1 HK 1198541 A1 HK1198541 A1 HK 1198541A1 HK 14112047 A HK14112047 A HK 14112047A HK 1198541 A1 HK1198541 A1 HK 1198541A1
Authority
HK
Hong Kong
Prior art keywords
factor viii
domain
reconstitution
stability
improving
Prior art date
Application number
HK14112047.2A
Other languages
English (en)
Chinese (zh)
Inventor
Carsten Horn
Sabine ZOLLNER
Hubert Metzner
Stefan Schulte
Original Assignee
Csl Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Csl Limited filed Critical Csl Limited
Publication of HK1198541A1 publication Critical patent/HK1198541A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK14112047.2A 2011-10-18 2012-10-18 Method for improving the stability of purified factor viii after reconstitution HK1198541A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161548601P 2011-10-18 2011-10-18
US61/548,601 2011-10-18
EP11185651 2011-10-18
EP11185651.4 2011-10-18
PCT/EP2012/070701 WO2013057219A1 (en) 2011-10-18 2012-10-18 Method for improving the stability of purified factor viii after reconstitution

Publications (1)

Publication Number Publication Date
HK1198541A1 true HK1198541A1 (en) 2015-05-15

Family

ID=48140377

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112047.2A HK1198541A1 (en) 2011-10-18 2012-10-18 Method for improving the stability of purified factor viii after reconstitution

Country Status (9)

Country Link
US (5) US9394353B2 (enExample)
EP (1) EP2768853A1 (enExample)
JP (2) JP2014531910A (enExample)
KR (1) KR20140084208A (enExample)
CN (1) CN103917554B (enExample)
AU (1) AU2012318292B2 (enExample)
CA (1) CA2850579A1 (enExample)
HK (1) HK1198541A1 (enExample)
WO (1) WO2013057219A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1198541A1 (en) 2011-10-18 2015-05-15 Csl Limited Method for improving the stability of purified factor viii after reconstitution
PL3666283T3 (pl) * 2013-03-15 2022-10-03 Bioverativ Therapeutics Inc. Formulacje polipeptydu czynnika viii
AU2015240354A1 (en) * 2014-04-01 2016-11-17 Advantech Bioscience Farmaceutica Ltda. Stabilization of Factor VIII without calcium as an excipient
MX2016012870A (es) * 2014-04-01 2017-05-12 Advantech Bioscience Farmacêutica Ltda Formulaciones de factor viii estables con bajo tenor de azucar - glicina.
PL3193911T3 (pl) * 2014-07-25 2024-03-11 Csl Behring Gmbh Ulepszone preparaty czynnika VIII do stosowania do leczenia hemofilii A
JP6516829B2 (ja) 2014-08-04 2019-05-22 シーエスエル、リミテッド 第ｖｉｉｉ因子製剤
JP6877469B2 (ja) 2016-06-24 2021-05-26 モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用
CN109689683A (zh) * 2016-06-24 2019-04-26 财团法人牧岩生命科学研究所 重组单链fvⅲ及其化学缀合物
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
US20200263196A1 (en) 2017-09-27 2020-08-20 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
CA3078625C (en) 2017-10-09 2023-01-17 Terumo Bct Biotechnologies, Llc Lyophilization container and method of using same
WO2019195056A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising stem cells
TW202014181A (zh) 2018-04-04 2020-04-16 美商希吉隆醫療公司 可植入顆粒及相關方法
MA53020A (fr) 2018-05-18 2021-05-05 Zhengzhou Gensciences Inc Protéine de fusion du fviii améliorée et utilisation associée
RS66972B1 (sr) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc Metode lečenja hemofilije a
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
CA3224729A1 (en) 2019-03-14 2020-09-17 Terumo Bct Biotechnologies, Llc Lyophilization loading tray assembly and system
EP3736286A1 (en) 2019-05-09 2020-11-11 Biotest AG Single chain factor viii molecule
WO2024081310A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease
EP4602155A1 (en) 2022-10-11 2025-08-20 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
JPH0788399B2 (ja) 1985-04-12 1995-09-27 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド 新規プロコアギュラント蛋白質
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5451521A (en) 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
IL84168A0 (en) 1986-10-15 1988-03-31 Rorer Int Overseas Human factor viii-c analogs,process for the preparation thereof and pharmaceutical compositions containing the same
JP2872255B2 (ja) 1987-01-30 1999-03-17 バイオジエン，インコーポレイティド ファクター▲ｖｉｉｉ▼の高収量生産法
EP0690126B1 (en) 1987-06-12 2001-11-28 Baxter Aktiengesellschaft Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US5605884A (en) 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
DE4111393A1 (de) 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
DE69735421T2 (de) 1996-04-24 2006-10-19 The Regents Of The University Of Michigan, Ann Arbor Gegen inaktivierung resistenter faktor viii
AU1598200A (en) 1998-10-23 2000-05-15 Trustees Of The University Of Pennsylvania, The Systemic delivery of gene products via skin
NZ516400A (en) 1999-07-13 2004-02-27 Biovitrum Ab Stable factor VIII compositions
EP1460131A3 (en) 2000-03-22 2005-06-01 Octagene GmbH Production of recombinant blood clotting factors in human cell lines
AU2002312660A1 (en) * 2001-05-31 2002-12-16 D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools
US20040192599A1 (en) 2001-06-15 2004-09-30 Schuh Andre C Gene therapy for hemophilia a
US7041635B2 (en) * 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
DE602004031390D1 (de) 2003-05-06 2011-03-24 Syntonix Pharmaceuticals Inc Gerinnungsfaktor VII-Fc chimäre Proteine zur Behandlung von hämostatischen Krankheiten
US20080070251A1 (en) 2006-06-30 2008-03-20 Kaufman Randal J Method of Producing Factor VIII Proteins by Recombinant Methods
EP3231440A1 (en) * 2006-12-22 2017-10-18 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
CN102427823A (zh) * 2009-03-24 2012-04-25 拜耳医药保健有限公司 因子viii变体及使用方法
CA2770609A1 (en) 2009-08-20 2011-02-24 Csl Behring Gmbh Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
GB0915480D0 (en) 2009-09-04 2009-10-07 Arecor Ltd Stable formulation of factor viii
HK1198541A1 (en) 2011-10-18 2015-05-15 Csl Limited Method for improving the stability of purified factor viii after reconstitution
US9534029B2 (en) 2012-10-03 2017-01-03 Csl Behring Ag Method of purifying proteins

Also Published As

Publication number Publication date
EP2768853A1 (en) 2014-08-27
CN103917554A (zh) 2014-07-09
US20190038722A1 (en) 2019-02-07
US20210308229A1 (en) 2021-10-07
US20200268854A1 (en) 2020-08-27
US11510968B2 (en) 2022-11-29
CN103917554B (zh) 2017-03-08
US20140249086A1 (en) 2014-09-04
WO2013057219A1 (en) 2013-04-25
US9956269B2 (en) 2018-05-01
JP2017114889A (ja) 2017-06-29
AU2012318292A1 (en) 2013-05-02
US20160367641A1 (en) 2016-12-22
AU2012318292B2 (en) 2015-08-20
US9394353B2 (en) 2016-07-19
US10537616B2 (en) 2020-01-21
CA2850579A1 (en) 2013-04-25
KR20140084208A (ko) 2014-07-04
US10881717B2 (en) 2021-01-05
JP2014531910A (ja) 2014-12-04

Similar Documents

Publication Publication Date Title
HK1198541A1 (en) Method for improving the stability of purified factor viii after reconstitution
EP2649173A4 (en) Dibasic esters utilized as terpene co-solvents, substitutes and/or carriers in tar sand/bitumen/asphaltene cleaning applications
WO2013078170A8 (en) Purification of anti-c-met antibodies
WO2011059295A3 (ko) 로봇 청소기 및 이의 제어 방법
WO2011103150A3 (en) Lyophilized preparations of bendamustine
WO2010123587A3 (en) New and improved actuators and related methods
WO2010114982A3 (en) Lyophilization cakes of proteasome inhibitors
MX2012013027A (es) Metodos mejorados para preparar escualeno.
EP2647655A4 (en) High molecular compound, method for producing same, and light-emitting element
WO2012025944A3 (en) Sitagliptin, salts and polymorphs thereof
PL2665826T3 (pl) Sposób fermentacyjnego wytwarzania aminokwasów zawierających siarkę
WO2012142302A3 (en) Biocatalytic process for preparing eslicarbazepine and analogs thereof
WO2012071451A3 (en) Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
WO2013089478A3 (ko) 신규 ｏ-포스포세린 설프하이드릴라아제를 이용하여 시스테인 또는 이의 유도체를 생산하는 방법
BRPI0922388A2 (pt) "processo para a produção de depsipeptídeos cíclicos, contendo ácido láctico e ácido láctico fenílico opticamente ativos, com 24 átomos no anel com auxílio de estirpes de fungos do tipo rosellinia bem como de outras espécies das xylariacenn".
WO2012168837A3 (en) Method of treating articles with carbon dioxide
MX2015010165A (es) Metodo para reducir el consumo de energia mediante acoplamiento termico.
AR082881A1 (es) Proceso para preparar un derivado de piperidina, intermediario para sintetizar un medicamento
WO2013026021A3 (en) Trka as a target for inhibiting app cleavage and/or progression of alzheimer's disease
WO2011009532A3 (de) 17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-derivate, verfahren zu deren herstellung und deren verwendung zur behandlung von krankheiten
ZA200905118B (en) Method for the production of switch ties, and switch tie produced according to said method
WO2012154460A3 (en) Method for producing bioderived dipropylene and tripropylene glycols without propylene oxide
WO2013167625A3 (fr) Tissu a fils releves en verre, en quartz ou en métal
WO2013092672A3 (en) Method for recombinant production of labyrinthopeptins and functional derivatives thereof
WO2010089267A3 (en) Method for producing 2-halogenomethylphenyl acetic acid derivatives